ADC Therapeutics Reports Q3 Revenue of $21 Million, Runway Into 2029
ADC Therapeutics reported Q3 2026 net product revenue of $21.0 million, up from $15.8 million a year earlier, and a net loss of $25.3 million. It ended September with $189.2 million in cash and cash equivalents.
ADC Therapeutics reported third-quarter 2026 net product revenue of $21.0 million, up from $15.8 million a year earlier, and a net loss of $25.3 million. The company ended September with $189.2 million in cash and cash equivalents and said its expected cash runway extends into 2029 following a fina…